알래스카의 비소세포폐암 임상 시험
비소세포폐암 관련 연구 13개가 알래스카 내 여러 지역에서 참여자를 모집하고 있습니다.
알래스카의 도시
공식 연구 텍스트(영어)
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Fairbanks Cancer Care Physicians, PC, Fairbanks
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT06758401Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Katmai Oncology Group, Anchorage
- Fairbanks Memorial Hospital, Fairbanks
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT04267848A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Alaska Oncology and Hematology, Anchorage
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 5. 업데이트됨 · NCT07144280A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Alaska Oncology and Hematology, Anchorage
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 5. 업데이트됨 · NCT06793215Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC
- Alaska Oncology and Hematology, Anchorage
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT07777822Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Fairbanks Memorial Hospital, Fairbanks
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT06418204Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- Fairbanks Memorial Hospital, Fairbanks
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT03191149Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- Alaska Oncology and Hematology, LLC, Anchorage
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 11. 2. 업데이트됨 · NCT06712316Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Anchorage
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 28. 업데이트됨 · NCT06357533Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Alaska Oncology & Hematology, LLC, Anchorage
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 23. 업데이트됨 · NCT06899126A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
- Alaska Oncology and Hematology, Anchorage
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 13. 업데이트됨 · NCT07128199A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Alaska Oncology and Hematology, Anchorage
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 7. 6. 업데이트됨 · NCT04389632Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Katmai Oncology Group, Anchorage
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 6. 3. 업데이트됨 · NCT05642572ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.